Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID | D0X1BJ | ||||
| Former ID | DIB001326 | ||||
| Drug Name | Denibulin | ||||
| Synonyms | Denibulin hydrochloride; ANG-600 series; ANG-615; MN-029; Second generation VTAs, Angiogene Pharmaceuticals; Second generation VTAs, MediciNova; Vascular targeting agents (benzimidazole carbamates), Angiogene Pharmaceuticals; Vascular targeting agents (benzimidazole carbamates), MediciNova | ||||
| Drug Type | Small molecular drug | ||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 1 | [548126] | ||
| Company | Angiogene Pharmaceuticals Ltd | ||||
| Formula | C18H19N5O3S | ||||
| Canonical SMILES | c12c([nH]c(n1)NC(=O)OC)ccc(c2)Sc1ccc(cc1)NC(=O)[C@H](C)<br />N | ||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Tubulin beta | Target Info | Inhibitor | [544311] | |
| PANTHER Pathway | Cytoskeletal regulation by Rho GTPase | ||||
| Huntington disease | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.
